Friday - August 1, 2025
Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients With Uncontrolled or Treatment Resistant Hypertension
July 15, 2025
WILMINGTON, Delaware, July 15 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo

*

Positive high-level results from . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products